Sanofi-Synthelabo Eloxatine

Company is beginning two Phase III trials for oxaliplatin as second-line treatment of metastatic colorectal cancer after Lilly gives up rights to oxaliplatin and returns product to Sanofi. Eloxatine received a negative recommendation for first-line treatment by FDA's Oncologic Drugs Advisory Committee in March, and FDA has told the company that "additional studies would be required prior to approval," Sanofi said